Published by Josh White on 7th June 2023
(Sharecast News) - Pharmaceuticals giant GSK announced on Wednesday that the European Commission has granted authorisation for 'Arexvy' - an adjuvant respiratory syncytial virus (RSV) vaccine - for active immunisation to prevent RSV-caused lower respiratory tract disease (LRTD) in adults 60 and older.
URL: http://www.digitallook.com/dl/news/story/33554501/...